Related Experiment Video
Updated: Jun 14, 2026
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
Published on: August 31, 2022
[Experimental study of HIF-1alpha antisense oligonucleotide on implanted human gastric cancer in nude mice]
Tao He1, Yong-Hao Li, Dian-Dong Wang
1Department of General Surgery, The First Affiliated Hospital, Baotou Medical School, China.
Objective:
To observe the effect of HIF-1alpha antisense oligonucleotide (HIF-1alpha ASOND) on implanted human gastric cancer in nude mice.
Methods:
BALB/c nude mice were subcutaneously transplanted with SCG-7901 tumor cells, then the mice were randomly divided into antisense oligonucleotide (ASOND) group, sense oligonucleotide (SOND) group and the control group. The HIF-1alpha ASOND complexed with cationic liposome, HIF-1alpha SOND complexed with cationic liposome and liposome were injected intra-tumorally in the above groups, respectively. Tumor growth curve in each group animals was observed. The tumor weight was measured and then the rate of inhibition was calculated. The morphological changes of tumor cells was observed under microscope. The expression of HIF-1alpha, VEGF and MVD in tumor tissue was determined by immunohistochemical methods.
Results:
The growth of tumor of ASOND group was significantly inhibited. There was statistically significant difference (P < 0.05) in the weight of tumor between ASOND group and control group. The inhibitory rates of ASOND group and SOND group were 47.94% and 16.88% respectively, and both inhibitory rates were significantly different (P < 0.01). The tumor tissue expression of HIF-1alpha, VEGF and MVD in ASOND group was significantly lower than those of SOND and the control groups (P < 0.01).
Conclusion:
In tumor tissue, the injection of HIF-1alpha ASOND to treat gastric carcinoma transplanted subcutaneously in nude mice can reduce the expression of HIF-1alpha, consequently reduce the formation of VEGF and new blood vessels, so as to achieve inhibition of tumor growth.
Insights
HIF-1alpha antisense oligonucleotide (HIF-1alpha ASOND) significantly inhibited gastric cancer growth in mice by reducing HIF-1alpha, VEGF, and MVD expression. This targeted approach offers a promising strategy for gastric carcinoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Context:
- Gastric carcinoma is a significant global health concern with limited effective treatments.
- Hypoxia-inducible factor 1-alpha (HIF-1alpha) plays a critical role in tumor growth and angiogenesis.
- Targeting HIF-1alpha presents a potential therapeutic strategy for gastric cancer.
Purpose:
- To evaluate the efficacy of HIF-1alpha antisense oligonucleotide (HIF-1alpha ASOND) in inhibiting implanted human gastric cancer in a mouse model.
- To assess the impact of HIF-1alpha ASOND on tumor growth, weight, and the expression of key angiogenic factors.
Summary:
- BALB/c nude mice bearing SCG-7901 gastric tumors were treated with HIF-1alpha ASOND, sense oligonucleotide (SOND), or control.
- HIF-1alpha ASOND treatment resulted in significant inhibition of tumor growth and reduced tumor weight compared to control groups.
- Immunohistochemical analysis revealed significantly lower expression of HIF-1alpha, VEGF, and microvessel density (MVD) in tumors treated with HIF-1alpha ASOND.
Impact:
- HIF-1alpha ASOND demonstrates significant anti-tumor activity against gastric cancer in vivo.
- The mechanism involves the downregulation of HIF-1alpha, leading to reduced VEGF expression and subsequent inhibition of angiogenesis.
- These findings support HIF-1alpha ASOND as a potential therapeutic agent for gastric carcinoma.
